Six senators are railing on Sanofi for its role in a Zika pricing dustup that’s gained considerable attention since last year.
Declining sales of Prevnar have urged Pfizer to seek compensation elsewhere, including a vaccine against Group B streptococcus.
With the expanding definition of “health” in play, does the category warrant a separate show in a program like the Lions?
BiondVax secured a €20 million loan from the European Investment Bank to advance its universal flu vaccine candidate.
Scientists at the University of Maryland, hoping to fill the hepatitis vaccine void, have secured funding from the NIH to work on a new candidate.
Merck & Co. may not be number one with a bullet in vaccines, but CEO Ken Frazier says the unit shouldn't be underestimated.
The Radboud University Medical Center in the Netherlands, the Instituto de Medicina Molecular Lisboa in Portugal, and PATH are collaborating on a human trial…
Bristol-Myers Squibb's Opdivo is in more vaccine combo studies than its PD-1/PD-L1 rivals, according to a new report.
Bharat Biotech has initiated a phase 1 trial of its Chikungunya vaccine, while Themis started a phase 2 of its own candidate.
Dendreon unveiled new data at ASCO showing Provenge generates a killer T-cell response that correlates with overall survival.
A Sanofi executive has explained the rationale behind the company’s Zika vaccine development plan and is issuing a defense against claims his company is out to…